Dianosic

Patient non-adherence with drug treatments, which causes 300,000 deaths a year and more than €300B loss of pharma revenuesin Europe and the United States, is an unsolved problem.

Dianosic is developing a solution to the major public health problem of non-compliance with medications. Using intranasal precision medicines, we optimize the efficacy and safety of treatments for the respiratory (chronic rhinitis, chronic sinusitis), neuropsychiatric (schizophrenia) and neurodegenerative (Parkinson) therapeutic areas.

Our solution is a resorbable, drug-eluting intranasal formulation, which takes the form of an insert releasing drugs of interest in a controlled, targeted and long-term manner.  This “ARIS” (Active resorbable Intranasal Scaffold") formulation is delivered in an otorhinolaryngology in-office setting under local anaesthesia and endoscopic control. Upon contact with the mucosa, the active ingredient is gradually released. The release is targeted, controlled and in reduced quantities, maximizing treatment efficacy while minimizing peripheral systemic effects. Treatment lasts from 6 to 12 months, freeing patients from having to take their treatment every day.